Romlusevimab

• Description :

  Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1][2].

• Product Name Alternative :

  BRII-198

• UNSPSC :

  12352203

• Target :

  SARS-CoV

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/romlusevimab.html

• Purity :

  95.00

• Solubility :

  H2O

• Smiles :

  [Romlusevimab]

• Molecular Weight :

  (145.126 kDa)

• References & Citations :

  [1]Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82 (12) :1327-1331.|[2]Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [2509447-08-7]